News

July 15, 2025

Frontage Strengthens Global GDDS and DMPK Leadership

EXTON, Pa., July 15, 2025 – Frontage Holdings Corporation announces the appointment of Dr. Sean Yu as Senior Vice President and Head of Global Drug Discovery Services (GDDS) and Drug Metabolism and Pharmacokinetics (DMPK) Services. Dr. Yaodong Huang, Senior Vice President of Frontage Chemistry Services, will serve as Co-Head of GDDS. Both will report to Co-Chief Executive Officer Dr. Wentao Zhang.

Dr. Sean Yu has over 30 years of experience from large pharma and CRO operations. He led DMPK Services at Frontage since joining in 2019 through the acquisition of RMI Laboratories, he founded in 2014 and led as CEO. He spent over 18 years at Merck & Co, has over 50 publications, and holds a PhD in Analytical Chemistry from Rutgers University, BS from Peking University, and a Management Certificate from Wharton Business School.

Dr. Yaodong Huang joined Frontage in 2024. Previously, he was Executive Vice President of Chemistry at Ocgene Biotech, leading over 350 professionals in R&D, production, and quality control. He has worked with SYNthesis Med Chem, ACME Biopharma, and Philips Research. Dr. Huang holds a PhD in Organic Chemistry from the University of California and MS from Fudan University and received the BR Baker Memorial Fellowship and Roche Bioscience Award.

Dr. Zhang stated, “Sean and Yaodong’s leadership has positioned our DMPK and Chemistry services as a trusted provider. The integration of global GDDS, Chemistry, and DMPK operations is well positioned to drive innovative drug discovery from initial leads to developmental candidates.”

Dr. Yu said, “I’m excited to position Frontage as a leading provider of GDDS and DMPK services globally.” Dr. Huang added, “I’m honored to co-lead with Dr. Yu and aim to drive exemplary growth as trusted partners to our customers.”